Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImClone Systems has enrolled the first patient in a disease-directed multicenter, multinational, open-label Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma or liver cancer.
Subscribe to our email newsletter
The primary objective of the study is to determine the progression-free survival of patients with previously untreated and inoperable liver cancer when treated with IMC-1121B. This Phase II study is designed to evaluate the efficacy, safety and pharmacology of IMC-1121B administered every two weeks by intravenous infusion.
The trial is enrolling patients with advanced, inoperable liver cancer who have not received prior chemotherapy or other systemic therapies for their disease. A total of 40 patients are expected to be enrolled.